SCHEMBL1756446

SCHEMBL1756446

Cc1cc2cc3c(C#C[Si](C(C)C)(C(C)C)C(C)C)c4cc5ccccc5cc4c(C#C[Si](C(C)C)(C(C)C)C(C)C)c3cc2cc1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 1/20 0.33
CACNB2 Q08289 1/20 0.33
CACNA1C Q13936 1/20 0.33
MAPT P10636 2/20 0.32
NQO2 P16083 1/20 0.32
KDM4E B2RXH2 2/20 0.31
LMNA P02545 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CYP1A2 P05177 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
CYP2C19 P33261 1/20 0.31
ELANE P08246 1/20 0.30
NPC1 O15118 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1270205 0.92 CACNA2D1 (0.35) CACNA2D1CACNB2CACNA1CMAPTKDM4E
SCHEMBL20044956 0.92 CACNA2D1 (0.35) CACNA2D1CACNB2CACNA1CMAPTKDM4E
SCHEMBL29360481 0.92 CACNA2D1 (0.37) CACNA2D1CACNB2CACNA1CMAPTNQO2
SCHEMBL336442 0.92 CACNA2D1 (0.37) CACNA2D1CACNB2CACNA1CMAPTNQO2
SCHEMBL18267813 0.90 CACNA2D1 (0.36) CACNA2D1CACNB2CACNA1CMAPTKDM4E
SCHEMBL651091 0.89 CACNA2D1 (0.33) CACNA2D1CACNB2CACNA1CKDM4ELMNA
SCHEMBL30360377 0.89 CACNA2D1 (0.35) CACNA2D1CACNB2CACNA1CMAPTKDM4E
SCHEMBL14514097 0.89 CACNA2D1 (0.35) CACNA2D1CACNB2CACNA1CMAPTKDM4E
SCHEMBL2161848 0.86 ESR1 (0.35) CACNA2D1CACNB2CACNA1CKDM4ELMNA
SCHEMBL27725041 0.85 CACNA2D1 (0.35) CACNA2D1CACNB2CACNA1CMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1880429-B1 POLYACENE AND SEMICONDUCTOR FORMULATION MERCK PATENT GMBH (DE) 2012-06-27 EP disclosed
US-7935960-B2 organic field effect transistors; introducing asymmetry into the polyacene derivative affects its solid-state order; combining with organic binder resin results in little or no reduction in charge mobility of the polyacene, even an increase in some instances MERCK PATENT GMBH (DE) 2011-05-03 US disclosed
US-7935960-B2 organic field effect transistors; introducing asymmetry into the polyacene derivative affects its solid-state order; combining with organic binder resin results in little or no reduction in charge mobility of the polyacene, even an increase in some instances MERCK PATENT GMBH (DE) 2011-05-03 US disclosed
US-7935960-B2 organic field effect transistors; introducing asymmetry into the polyacene derivative affects its solid-state order; combining with organic binder resin results in little or no reduction in charge mobility of the polyacene, even an increase in some instances MERCK PATENT GMBH (DE) 2011-05-03 US disclosed
US-20100308304-A1 ELECTRONIC SHORT CHANNEL DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR FORMULATION MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-09 US disclosed
EP-1986247-A1 Polyacene and semiconductor Formulation MERCK PATENT GmbH (DE) 2008-10-29 EP disclosed
US-20080191199-A1 Polyacene and Semiconductor Formulation FLEXENABLE TECHNOLOGY LIMITED (GB) 2008-08-14 US disclosed
US-20080191199-A1 Polyacene and Semiconductor Formulation FLEXENABLE TECHNOLOGY LIMITED (GB) 2008-08-14 US disclosed
US-20080191199-A1 Polyacene and Semiconductor Formulation FLEXENABLE TECHNOLOGY LIMITED (GB) 2008-08-14 US disclosed
EP-1880429-A1 POLYACENE AND SEMICONDUCTOR FORMULATION Merck Patent GmbH (DE) 2008-01-23 EP disclosed
WO-2006119853-A1 POLYACENE AND SEMICONDUCTOR FORMULATION MERCK PATENT GMBH (DE) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080191199-A1 Polyacene and Semiconductor Formulation OR51E2, PIEZO1, FDFT1 CACNA2D1 1110/4885CACNB2 1262/4885CACNA1C 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.